BiotechTube

enzastaurin

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Mantle-Cell Lymphoma

Conditions

Mantle-Cell Lymphoma

Trial Timeline

Mar 1, 2004 → May 1, 2008

NCT ID
NCT00088205

About enzastaurin

enzastaurin is a phase 2 stage product being developed by Eli Lilly for Mantle-Cell Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00088205. Target conditions include Mantle-Cell Lymphoma.

What happened to similar drugs?

0 of 1 similar drugs in Mantle-Cell Lymphoma were approved

Approved (0) Terminated (0) Active (1)
🔄Pirtobrutinib + Ibrutinib + Acalabrutinib + ZanubrutinibEli LillyPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (11)

NCT IDPhaseStatus
NCT01432951Phase 1Completed
NCT00744991Phase 2Completed
NCT00718419Phase 2Completed
NCT00542919Phase 2Completed
NCT00475644Phase 2Completed
NCT00452257Phase 1Completed
NCT00420381Phase 2Completed
NCT00428714Phase 2Completed
NCT00309140Phase 2Completed
NCT00088205Phase 2Completed
NCT00190723Phase 2Completed

Competing Products

9 competing products in Mantle-Cell Lymphoma

See all competitors
ProductCompanyStageHype Score
Pirtobrutinib + Ibrutinib + Acalabrutinib + ZanubrutinibEli LillyPhase 3
44
VenetoclaxAbbViePhase 2
35
ABT-199 and Ibrutinib CombinationAbbViePhase 1
29
Acalabrutinib + R-CHOP standard of care + Acalabrutinib combination with Rituximab + Acalabrutinib monotherapyAstraZenecaPhase 2
42
SCH 727965 + Bortezomib + AlemtuzumabMerckPhase 2
27
Obinutuzumab + Glofitamab + Venetoclax Oral Product + Zanubrutinib Oral CapsuleRochePhase 2
42
PD-0332991PfizerPhase 1
29
Copanlisib (BAY80-6946)BayerPhase 2
24
Yttrium-ibritumomab (Zevalin) + RituximabBiogenPhase 2
32